Press Releases

pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma WATERTOWN, Mass., Jun 14, 2011 (BUSINESS WIRE) -- Drug delivery company pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) today announced the commencement of a Phase

pSivida Announces Resubmission of New Drug Application for ILUVIEN(R) WATERTOWN, Mass., May 13, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its

pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2011 WATERTOWN, Mass., May 10, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product

pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN(R) in Diabetic Macular Edema WATERTOWN, Mass., May 03, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Corp. Announces Third Quarter 2011 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., May 03, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2010 WATERTOWN, Mass., Feb 09, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product

pSivida Announces Positive Results from the 36 Month Readout of Completed Phase 3 FAME(TM) Study of ILUVIEN(R) in Patients with Diabetic Macular Edema WATERTOWN, Mass., Feb 03, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery

pSivida Corp. Announces Second Quarter 2011 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Feb 02, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Completes Previously Announced Registered Direct Financing WATERTOWN, Mass., Jan 24, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug

pSivida Announces $10.75 Million Registered Direct Financing WATERTOWN, Mass., Jan 19, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN

FDA Issues Complete Response Letter Regarding New Drug Application for ILUVIEN(R) WATERTOWN, Mass., Dec 23, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the

pSivida Corp. to Present at the Maxim Group Growth Conference WATERTOWN, Mass., Nov 16, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate

pSivida Corp. Reports Results for the First Quarter Ended September 30, 2010 WATERTOWN, Mass., Nov 05, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product

pSivida Corp Awarded Two Therapeutic Discovery Project Grants Totaling $489,000 WATERTOWN, Mass., Nov 03, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of back-of-the-eye disease including the

pSivida Corp Announces First Quarter 2011 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Oct 28, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of

pSivida Ranked15th on 2010 Technology Fast 500(TM), Deloitte's Ranking of Fastest Growing Companies in North America WATERTOWN, Mass., Oct 20, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of

- Iluvien NDA Filed and Granted Priority Review

pSivida Corp Announces Fourth Quarter and Fiscal Year 2010 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Sep 15, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of sustained release drug delivery systems for

pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference BOSTON, Sep 09, 2010 (BUSINESS WIRE) -- pSivida Corp, (NASDAQ:PSDV)(ASX:PSD), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it

pSivida Announces Iluvien(R) Receives FDA Priority Review for Treatment of Diabetic Macular Edema WATERTOWN, Mass., Aug 31, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat